RepliCel Life Sciences Inc
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include … Read more
RepliCel Life Sciences Inc (REPCF) - Total Assets
Latest total assets as of September 2025: $13.66K USD
Based on the latest financial reports, RepliCel Life Sciences Inc (REPCF) holds total assets worth $13.66K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
RepliCel Life Sciences Inc - Total Assets Trend (2002–2024)
This chart illustrates how RepliCel Life Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
RepliCel Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
RepliCel Life Sciences Inc's total assets of $13.66K consist of 39.0% current assets and 61.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.2% |
| Accounts Receivable | $35.37K | 24.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how RepliCel Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RepliCel Life Sciences Inc's current assets represent 39.0% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, up from 0.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 24.1% of total assets.
RepliCel Life Sciences Inc Competitors by Total Assets
Key competitors of RepliCel Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
RepliCel Life Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - RepliCel Life Sciences Inc generates 2.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - RepliCel Life Sciences Inc is currently not profitable relative to its asset base.
RepliCel Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.02 | 0.08 |
| Quick Ratio | 0.01 | 0.02 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.15 Million | $ -2.25 Million | $ -2.05 Million |
RepliCel Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between RepliCel Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -48.9% |
| Total Assets | $147.10K |
| Market Capitalization | $7.36K USD |
Valuation Analysis
Below Book Valuation: The market values RepliCel Life Sciences Inc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: RepliCel Life Sciences Inc's assets decreased by 48.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for RepliCel Life Sciences Inc (2002–2024)
The table below shows the annual total assets of RepliCel Life Sciences Inc from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $147.10K | -48.89% |
| 2023-12-31 | $287.79K | -63.95% |
| 2022-12-31 | $798.22K | +34.88% |
| 2021-12-31 | $591.79K | +40.58% |
| 2020-12-31 | $420.96K | -16.72% |
| 2019-12-31 | $505.47K | -84.34% |
| 2018-12-31 | $3.23 Million | +281.48% |
| 2017-12-31 | $846.03K | -53.72% |
| 2016-12-31 | $1.83 Million | +339.55% |
| 2015-12-31 | $415.92K | -80.58% |
| 2014-12-31 | $2.14 Million | +4.33% |
| 2013-12-31 | $2.05 Million | +306.02% |
| 2012-12-31 | $505.49K | -19.94% |
| 2011-12-31 | $631.42K | -51.75% |
| 2010-12-31 | $1.31 Million | +1335.91% |
| 2009-12-31 | $91.14K | +59.70% |
| 2008-12-31 | $57.07K | +59.06% |
| 2007-12-31 | $35.88K | -88.32% |
| 2006-12-31 | $307.29K | -90.53% |
| 2005-12-31 | $3.25 Million | +18356.15% |
| 2004-12-31 | $17.59K | 0.00% |
| 2003-12-31 | $17.59K | -34.72% |
| 2002-12-31 | $26.95K | -- |